HepaTx - About the company
HepaTx is a seed company based in Palo Alto (United States), founded in 2015 by Pier Federico Gherardini, Eric Schuur and Bruce R Davis. It operates as a Developing off-the-shelf cell therapies for late-stage liver disease. HepaTx has raised $150K in funding from Y Combinator. The company has 166 active competitors, including 54 funded and 51 that have exited. Its top competitors include companies like Nimbus Therapeutics, Intercept Pharmaceuticals and Madrigal Pharmaceuticals.
Company Details
Developing off-the-shelf cell therapies for late-stage liver disease, offering regenerative medicine solutions as an alternative to liver transplants. The company focuses on stem cell-based therapies to address the critical need for accessible and effective liver disease treatments. Their approach involves a scalable manufacturing process, aiming to make liver regeneration clinically and economically practical. The company collaborates with entrepreneurial pioneers and is supported by investors, driving technology development and market reach. They are committed to educating the world about their innovative approach and offer opportunities for investment and career growth. The company's pipeline includes treatments for various liver diseases, utilizing an allogeneic cell therapy product for on-demand availability. This is a B2B biotech company with a social impact.
- Website
- hepatx.com
- Social
Key Metrics
Founded Year
2015
Location
Palo Alto, United States
Stage
Seed
Total Funding
$150K in 3 rounds
Latest Funding Round
Investors
Ranked
77th among 166 active competitors
Employee Count
3 as on Apr 30, 2026
Similar Companies
Sign up to download HepaTx's company profile
HepaTx's funding and investors
HepaTx has raised a total funding of $150K over 3 rounds. Its first funding round was on Sep 15, 2017. Its latest funding round was a Grant (prize money) round on Sep 01, 2019 for $*****. 1 investor participated in its latest round. HepaTx has 7 institutional investors.
Here is the list of recent funding rounds of HepaTx:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Sep 01, 2019 | 1252493 | Grant (prize money) | 6534005 | 8949344 | 3009575 | 6448502 |
Aug 21, 2018 | 8301618 | Seed | 9547110 | 7801851 | 5646746 | 5769803 |
Sep 15, 2017 | 3730490 | Grant (prize money) | 7504958 | 7352180 | 3852268 |
Access funding benchmarks and valuations. Sign up today!View details of HepaTx's funding rounds and investors
HepaTx's founders and board of directors
Founder? Claim ProfileHere are the details of HepaTx's key team members:
- Pier Federico Gherardini: Co-Founder of HepaTx.
- Eric Schuur: Co-Founder, President & CEO of HepaTx.
- Bruce R Davis: Co-Founder of HepaTx.
View details of HepaTx's Founder profiles and Board Members
HepaTx's employee count trend
HepaTx has 3 employees as of Apr 26. Here is HepaTx's employee count trend over the years:
Uncover HepaTx's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
HepaTx's Competitors and alternates
Top competitors of HepaTx include Nimbus Therapeutics, Intercept Pharmaceuticals and Madrigal Pharmaceuticals. Here is the list of Top 10 competitors of HepaTx, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Nimbus Therapeutics 2009, Cambridge (United States), Series F | Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases | $637M | 69/100 | |
2nd | Intercept Pharmaceuticals 2002, New York City (United States), Acquired | Developer of therapeutics to treat progressive non-viral liver diseases | $121M | 67/100 | |
3rd | Madrigal Pharmaceuticals 2011, Conshohocken (United States), Acquired | Develops small molecule drugs for the treatment of cardiovascular and metabolic diseases and non-alcoholic steatohepatitis | $38.4M | 65/100 | |
4th |  Mammoth 2017, Brisbane (United States), Series D | Provider of molecular diagnostics platform by using CRISPR technology | $271M | 65/100 | |
5th |  Mirum Pharmaceuticals 2018, Menlo Park (United States), Public | Developer of small molecule based therapeutics to treat rare diseases | $120M | 64/100 | |
6th | Developer of a novel treatment for metabolic diseases | $83M | 63/100 | ||
7th |  Ochre Bio 2019, Oxford (United Kingdom), Series A | Developer of ribonucleic acid therapies for treating chronic liver disease | $39.7M | 62/100 | |
8th | Enyo Pharma 2014, Lyon (France), Series C | Developer of therapeutics for diseases with impaired kidney function | $120M | 62/100 | |
9th | Jasper Therapeutics 1999, Redwood City (United States), Series A | Developer of therapeutics for chronic diseases by targeting mast cells and stem cells | $50M | 62/100 | |
10th | HemoGenyx 2014, Buffalo (United States), Public | Developer of cell and gene therapies to treat blood diseases and viral infections | - | 62/100 | |
77th | HepaTx 2015, Palo Alto (United States), Seed | Developing off-the-shelf cell therapies for late-stage liver disease | $150K | 38/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on HepaTx's competitors? Click here to see the top ones
HepaTx's Investments and acquisitions
HepaTx has made no investments or acquisitions yet.
News related to HepaTx
•
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about HepaTx
Explore our recently published companies
- Zygobit - Sahibzada Ajit Singh Nagar based, 2023 founded, Unfunded company
- HeyOz - Wilmington based, 2020 founded, Unfunded company
- Neene - Bengaluru based, 2022 founded, Unfunded company
- Ccmboulder - Unfunded company
- Beckerandbecker - Unfunded company
- Ekjal - Noida based, 2021 founded, Funding Raised company
